Publications by authors named "Brian Scheckner"

Claim this Profile
I
Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
Russell Rosenberg, Michael J Thorpy, Yves Dauvilliers, Paula K Schweitzer, Gary Zammit, Brian Scheckner

J Clin Sleep Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy.
Aatif M Husain, Shay Bujanover, Robert Ryan, Brian Scheckner, Jed Black

J Clin Sleep Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years.
Frank A López, Ann Childress, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner

J Atten Disord· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
Ann C Childress, Valerie Arnold, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner

J Atten Disord· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes with lisdexamfetamine dimesylate in children who have attention-deficit/hyperactivity disorder with emotional control impairments.
Alain Katic, Bryan Dirks, Thomas Babcock, Brian Scheckner, Ben Adeyi

J Child Adolesc Psychopharmacol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use.
Rakesh Jain, Thomas Babcock, Teodor Burtea, Bryan Dirks, Ben Adeyi, Brian Scheckner

Adv Ther· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate.
Robert L Findling, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner

J Child Adolesc Psychopharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Greg W Mattingly, Richard H Weisler, Joel Young, Ben Adeyi, Bryan Dirks, Brian Scheckner

BMC Psychiatry· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
Thomas Babcock, Bryan Dirks, Ben Adeyi, Brian Scheckner

BMC Pharmacol Toxicol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically relevant changes in emotional expression in children with ADHD treated with lisdexamfetamine dimesylate.
Alain Katic, Lawrence Ginsberg, Rakesh Jain, Ben Adeyi, Bryan Dirks, Brian Scheckner

J Atten Disord· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate.
Greg Mattingly, Richard Weisler, Bryan Dirks, Thomas Babcock, Ben Adeyi, Brian Scheckner

Innov Clin Neurosci· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults.
Thomas E Brown, Matthew Brams, Maria Gasior, Ben Adeyi, Thomas Babcock, Brian Scheckner

Curr Med Res Opin· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex subgroup analysis of treatment response to lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder.
James J McGough, Michael Greenbaum, Ben Adeyi, Thomas Babcock, Brian Scheckner

J Clin Psychopharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis.
Rakesh Jain, Thomas Babcock, Teodor Burtea, Bryan Dirks, Ben Adeyi, Brian Scheckner

Child Adolesc Psychiatry Ment Health· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physician perception of clinical improvement in children with attention-deficit/hyperactivity disorder: a post hoc comparison of lisdexamfetamine dimesylate and mixed amphetamine salts extended release in a crossover analog classroom study.
Frank A López, Brian Scheckner, Ann C Childress

Neuropsychiatr Dis Treat· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.
Lawrence Ginsberg, Alain Katic, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner

Curr Med Res Opin· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.
Atilla Turgay, Lawrence Ginsberg, Elias Sarkis, Rakesh Jain, Ben Adeyi, Brian Scheckner

J Child Adolesc Psychopharmacol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of pain syndromes with venlafaxine.
Dale R Grothe, Brian Scheckner, Dominick Albano

Pharmacotherapy· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis